Verve Therapeutics

Verve Therapeutics is a clinical-stage genetic medicines company focused on developing single-course in vivo gene editing treatments for cardiovascular disease. The enterprise utilizes base editing systems encapsulated in liver-directed lipid nanoparticles to permanently inactivate disease-causing genes such as PCSK9 and ANGPTL3, dramatically lowering blood cholesterol levels. By shifting heart disease treatment from daily pills to one-time genomic edits, Verve Therapeutics aims to transform cardiovascular healthcare.